Article Versions Notes

Leal AS, Moerland JA, Zhang D, Carapellucci S, Lockwood B, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers. 2021; 13(19):5004. https://doi.org/10.3390/cancers13195004

Leal, Ana S., Jessica A. Moerland, Di Zhang, Sarah Carapellucci, Beth Lockwood, Teresa Krieger-Burke, Bilal Aleiwi, Edmund Ellsworth, and Karen T. Liby. 2021. "The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer" Cancers 13, no. 19: 5004. https://doi.org/10.3390/cancers13195004

Leal, A. S., Moerland, J. A., Zhang, D., Carapellucci, S., Lockwood, B., Krieger-Burke, T., Aleiwi, B., Ellsworth, E., & Liby, K. T. (2021). The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers, 13(19), 5004. https://doi.org/10.3390/cancers13195004